DoH Policies screened during the period – 1 April 2026 – 30 June 2026
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- Department of Health Breastfeeding Action Plan
- Learning Disability Service Model (LDSM) - We Matter
- Making Life Better (MLB) -Thematic Action Plan to Refresh and Reshape Collaborative Action to Improve Health and Reduce Health Inequalities
- Neighbourhood Model of Health and Wellbeing
- NICE Clinical Guideline NG256 - Kidney cancer diagnosis and management
- NICE Technology Appraisal TA1145 - Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma
- NICE Technology Appraisal TA1146 - Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors
- NICE Technology Appraisal TA1147 - Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over
- NICE Technology Appraisal TA1148 - Sodium zirconium cyclosilicate for treating hyperkalaemia
- NICE Technology Appraisal TA1149 - Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma
- NICE Technology Appraisal TA1150 - Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer
- NICE Technology Appraisal TA1152 - Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
- NICE Technology Appraisal TA1153 - Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment
- NICE Technology Appraisal TA1155 - Rozanolixizumab for treating antibody-positive generalised myasthenia gravis
- NICE Technology Appraisal TA1156 - Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy
- NICE Technology Appraisal TA1157 - Givinostat for treating Duchenne muscular dystrophy in people 6 years and over
- NICE Technology Appraisal TA1158 - Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer
- NICE Technology Appraisal TA1159 - Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment
- NICE Technology Appraisal TA1160 - Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma
- NICE Technology Appraisal TA1161 - Sotatercept for treating pulmonary arterial hypertension
- NICE Technology Appraisal TA1162 - Nusinersen and risdiplam for treating spinal muscular atrophy
- NICE Technology Appraisal TA1164 - Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment
- NICE Technology Appraisal TA1165 - Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
- NICE Technology Appraisal TA1166 - Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils
- NICE Technology Appraisal TA1167 - Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
- NICE Technology Appraisal TA1169 - Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
- NICE Technology Appraisal TA1170 - Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
- NICE Technology Appraisal TA1171 - Seladelpar for previously treated primary biliary cholangitis
- NICE Technology Appraisal TA1172 - Atogepant for treating migraine
- NICE Technology Appraisal TA1173 - Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor
- The “Living Well” Community Pharmacy Service
- The Firefighters’ Pension Scheme (Amendment) Regulations (NI) 2026 – Proposed updates to member contribution structure
- The New Firefighters’ Pension Scheme (Amendment) Order (NI) 2026 – Matthews Amendments
- The Tobacco Retailer (Fixed Penalty) (Amount) (Amendment) Regulations (Northern Ireland) 2026